Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Balsalazide

A Prakash1, C M Spencer

  • 1Adis International Limited, Auckland, New Zealand.

Drugs
|July 17, 1998
PubMed
Summary
This summary is machine-generated.

Balsalazide effectively induces and maintains remission in ulcerative colitis patients, offering faster symptom relief than mesalazine. It also shows a superior tolerability profile compared to sulfasalazine.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Computer-aided detection thresholds can guide repeat rapid molecular testing in TB screening.

IJTLD open·2026
Same author

Exploring the differences in the tumor microenvironment and immuno-oncologic targets in pancreatic ductal adenocarcinomas (PDAC) according to <i>KRAS</i> mutational status.

ESMO gastrointestinal oncology·2026
Same author

Search for B^{0}→K^{*0}τ^{+}τ^{-} Decays at the Belle II Experiment.

Physical review letters·2025
Same author

Search for a Dark Higgs Boson Produced in Association with Inelastic Dark Matter at the Belle II Experiment.

Physical review letters·2025
Same author

Uncovering PD-L1 among immune cell predictive biomarkers and actionable genetic alterations in anal squamous-cell carcinomas in the era of immunotherapy.

ESMO open·2025
Same author

NK cell line modified to express a potent, DR5 specific variant of TRAIL, show enhanced cytotoxicity in ovarian cancer models.

Heliyon·2024
Same journal

Ecnoglutide: First Approvals.

Drugs·2026
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Internal Medicine

Background:

  • Ulcerative colitis (UC) is a chronic inflammatory bowel disease.
  • Sulfasalazine and mesalazine are common UC treatments with varying efficacy and tolerability.
  • Balsalazide, a prodrug of mesalazine, offers an alternative therapeutic option.

Purpose of the Study:

  • To evaluate the efficacy of balsalazide in inducing and maintaining remission in ulcerative colitis patients.
  • To compare the efficacy and tolerability of balsalazide with mesalazine and sulfasalazine.
  • To assess the speed of symptom relief with balsalazide treatment.

Main Methods:

  • Clinical trials comparing balsalazide (6.75 g/day and 2 g/day or 6 g/day) with mesalazine (2.4 g/day and 1.5 g/day) and sulfasalazine (3 g/day and 2 g/day).

Related Experiment Videos

  • Assessment of remission induction over 8- and 12-week periods.
  • Evaluation of remission maintenance in long-term studies.
  • Analysis of symptom relief and patient tolerability, including in patients intolerant to sulfasalazine.

    • Main Results:

    • Balsalazide 6.75 g/day was more effective than mesalazine 2.4 g/day for inducing remission and provided more prompt symptom relief.
    • Balsalazide 6.75 g/day demonstrated comparable efficacy to sulfasalazine 3 g/day in inducing remission.
    • In long-term studies, balsalazide showed comparable efficacy to sulfasalazine and mesalazine in maintaining remission.
    • Balsalazide exhibited a significantly better tolerability profile than sulfasalazine, with 70% of sulfasalazine-intolerant patients tolerating balsalazide.

    Conclusions:

    • Balsalazide is an effective treatment for both inducing and maintaining remission in ulcerative colitis.
    • Balsalazide offers a favorable alternative to mesalazine and sulfasalazine, particularly regarding speed of symptom relief and tolerability.
    • The improved tolerability of balsalazide makes it a viable option for patients who cannot tolerate sulfasalazine.